Dec. 21, 2017
Dissolution of Create Vaccine Company, Ltd.
Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Masayo Tada "Sumitomo Dainippon Pharma"), Japan BCG Laboratory (Head Office: Bunkyo-ku, Tokyo; President and CEO: Kazunobu Hayashi "Japan BCG") and Innovation Network Corporation of Japan (Head Office: Chiyoda-ku, Tokyo; President and COO: Mikihide Katsumata "INCJ") jointly announce that the three companies have agreed to the dissolution of Create Vaccine Company, Ltd. (Head Office: Osaka, Japan; President: Atsushi Tsuchida "Create Vaccine"), in which they have made a joint investment, as described below.
1. Rationale behind the dissolution
Create Vaccine was established by Sumitomo Dainippon Pharma and Japan BCG for the purposes of developing and marketing novel tuberculosis vaccines, and was jointly invested in by Sumitomo Dainippon Pharma, Japan BCG and INCJ. Since 2013, Create Vaccine has been engaged in joint development of novel tuberculosis vaccines, which incorporated a recombinant human parainfluenza Virus type-2 vector technology, together with the National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN) and Aeras, a non-profit organization. With the termination of this joint development, Sumitomo Dainippon Pharma, Japan BCG and INCJ have decided to dissolve Create Vaccine.
2. Outline of Create Vaccine Company, Ltd.
|（１）||Create Vaccine Company, Ltd.|
|（２）||6-8, Doshomachi 2-chome, Chuo-ku, Osaka|
|（３）||Atsushi Tsuchida (President)|
|（４）||Research, development, processing, manufacture, sale, and import/export of tuberculosis vaccines|
|（５）||¥425 million (As of December 21, 2017)|
|（６）||July 31, 2013|
|（７）||Sumitomo Dainippon Pharma：33.40%, Japan BCG：33.30%, INCJ：33.30% (As of December 21, 2017)|
*A description of joint investment into Create Vaccine Company, Ltd., please refer to the announcement made on May 22, 2014.